TrialBlood2021

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.

Delphine Réa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.